The economics of effective AIDS treatment in Thailand

AIDS

Volumn 21, Issue SUPPL. 4, 2007, Pages

  Over, Mead ^a   Revenga, Ana ^b   Masaki, Emiko ^c   Peerapatanapokin, Wiwat ^d   Gold, Julian ^e   Tangcharoensathien, Viroj ^f   Thanprasertsuk, Sombat ^f  

^a CENTER FOR GLOBAL DEVELOPMENT   (United States)

^b WORLD BANK   (United States)

^c ASIAN DEVELOPMENT BANK   (Philippines)

^d EAST WEST CENTER   (United States)

^e Albion Street Centre ^*  (Australia)

^f MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

Antiretroviral; ART; Cost; Cost effectiveness; Demand; Economic; Elasticity; Fiscal; HAART; HIV; Multinomial logit; NAPHA; Projection; Survival; VCT; Voluntary counseling and testing

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR PLUS SAQUINAVIR; STAVUDINE; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BUDGET; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE TRANSMISSION; DRUG COST; EPIDEMIOLOGICAL DATA; FUNDING; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LICENSING; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCALE UP; THAILAND;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COST-BENEFIT ANALYSIS; DRUG COSTS; FINANCING, GOVERNMENT; GOVERNMENT PROGRAMS; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MODELS, ECONOMETRIC; PATIENT COMPLIANCE; THAILAND;

EID: 34447319414     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000279713.39675.1c     Document Type: Article

References (34)

1. Thailand National HIV and AIDS Program. Towards universal access by 2010. Bangkok: Government of Thailand, Ministry of Public Health, Department of Disease Control; 2006.
2. Revenga A, Over AM, Masaki E, Peerapatanapokin W, Gold J, Tangcharoensathien V, et al. The economics of effective AIDS treatment: evaluating policy options for Thailand. Washington, DC: World Bank; 2006.
3. Ministry of Public Health. NAPHA report for March 2004. Bangkok, Thailand: Ministry of Public Health; 2004.
4. Thai Working Group. Projections for HIV/AIDS in Thailand: 2000-2020. Bangkok, Thailand: Karnsana Printing Press; 2001.
5. Gold J, Duncombe C, Ratanasuwan W, Wilson D, Ford N. Clinical background paper for expanding access to ART in Thailand report. Bangkok, Thailand and Washington, DC: Ministry of Public Health/The World Bank; 2005.
6. UNAIDS, UNFPA. 2002 Thailand country profile. HIV/AIDS situation in Thailand and national response to the epidemic. Bangkok, Thailand: Joint United Nations Programme on HIV/AIDS in Thailand; 2002.
7. Brown T, Peerapatanapokin W. The Asia epidemic model: a process model for exploring HIV policy and program alternatives in Asia. Sex Transm Inf 2004; 80:19-24.
8. Bureau of AIDS TaSTI. Data on costs. Bangkok: Government of Thailand, Ministry of Public Health; 2004.
9. World Bank. Confronting AIDS: public priorities in a global epidemic. New York: Oxford University Press; 1999.
10. Over M, Marseille E, Sudhakar K, Gold J, Gupta I, Indrayan A, et al. Antiretroviral therapy and HIV prevention in India: modeling costs and consequences of policy options. Sex Transm Dis 2006; 33 (10 Suppl.):S145-S152.
11. World Bank. Social Monitor Thailand: Thailand's response to AIDS: building on success, confronting the future. Washington, DC: World Bank; 2000.
12. Division of Epidemiology. Monthly epidemiological surveillance report. Bangkok: Government of Thailand, Ministry of Public Health; 2006.
13. Over M, Piot P. Human immunodeficiency virus infection and other sexually transmitted diseases in developing countries: public health importance and priorities for resource allocation. J Infect Dis 1996; 174 (Suppl. 2):S162-S175.
14. Teutsch SM. A framework for assessing the effectiveness of disease and injury prevention. MMWR Recomm Rep 1992; 41:1-12.
15. Dukers NH, Goudsmit J, de Wit JB, Prins M, Weverling GJ, Coutinho RA. Sexual risk behaviour relates to the virological and immunological improvements during highly active antiretroviral therapy in HIV-1 infection. AIDS 2001; 15:369-378.
16. Stolte IG, Dukers NHTM, de Wit JBF, Fennema JSA, Coutinho RA. Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAART. Sex Transm Infect 2001; 77:184-186.
17. Van de Ven P, Rawstorne P, Nakamura T, Crawford J, Kippax S. HIV treatments optimism is associated with unprotected anal intercourse with regular and with casual partners among Australian gay and homosexually active men. Int J STD AIDS 2002; 13:181-183.
18. Van de Ven P, Mao L, Fogarty A, Rawstorne P, Crawford J, Prestage G, et al. Undetectable viral load is associated with sexual risk taking in HIV serodiscordant gay couples in Sydney. AIDS 2005; 19:179-184.
19. Over M, Heywood P, Gold J, Gupta I, Hira S, Marseille E. HIV/AIDS prevention and treatment in India: modeling the costs and consequences. Washington, DC: World Bank; 2004.
20. McFadden D. Conditional logit analysis of qualitative choice behavior. In: Zarembka P, editor. Frontiers in econometrics. New York: Academic Press; 1974.
21. Goldie SJ, Yazdanpanah Y, Losina E, Weinstein MC, Anglaret X, Walensky RP, et al. Cost-effectiveness of HIV treatment in resource-poor settings - the case of Cote d'Ivoire. N Engl J Med 2006; 355:1141-1153.
22. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR, Sax PE, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11-19.
23. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55:1-17.
24. Lifson AR, Rybicki SL. Routine opt-out HIV testing. Lancet 2007; 369:539-540.
25. Weiser SD, Heisler M, Leiter K, Percy-de KF, Tlou S, DeMonner S, et al. Routine HIV testing in Botswana: a population-based study on attitudes, practices, and human rights concerns. PLoS Med 2006; 3:e261.
26. Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, et al. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 43 (Suppl. 1): S113-S118.
27. Medecins Sans Frontieres. 2005 Operational overview. Medecins Sans Frontieres; web site accessed 6/7/07: http://www.doctorswithoutborders.org/ publications/ar/i2005/thailand.cfm
28. Ministry of Public Health. Data on costs from the Bureau of AIDS, Tuberculosis, and Sexually Transmitted Infections. Bangkok: Ministry of Public Health; 2004.
29. World Health Organization, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report. Geneva: WHO; April 2007.
30. Ford N, Wilson D, Lotrowska M, Costa Chaves G, Kijtiwatchakul K. Sustaining access to antiretroviral therapy in developing countries: lessons from Brazil and Thailand. AIDS 2007; 21: in press.
31. Supakakunti S, Phetnoi W, Tsunekawa K. An evaluation of economic impacts of improving access to care to highly active therapy (HAART) program for HIV/AIDS patients in Thailand. Bangkok, Thailand: World Health Organization, Thailand and WHO Collaborating Centre for Centre for Health Economics, Faculty of Economics, Chulalongkorn University; 2004.
32. Masaki E. Background paper on evaluating financial implication of antiretroviral treatment (ART) policy in Thailand. Washington, DC: World Bank; 2004.
33. Teerawattananon Y, Mugford M, Tangcharoensathien V. Economic evaluation of palliative management versus peritoneal dialysis and hemodialysis for end-stage renal disease: evidence for coverage decisions in Thailand. Value Health 2007; 10:61-72.
34. Laxminarayan R, Mills AJ, Breman JG, Measham AR, Alleyne G, Claeson M, et al. Advancement of global health: key messages from the Disease Control Priorities Project. Lancet 2006; 367:1193-1208.